Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma.

Liu Z, Zhao X, Mao H, Baxter PA, Huang Y, Yu L, Wadhwa L, Su JM, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Hurwitz RL, Lau CC, Chintagumpala M, Blaney SM, Li XN.

Neuro Oncol. 2013 Sep;15(9):1173-85. doi: 10.1093/neuonc/not065. Epub 2013 May 7.

2.

A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.

Yu L, Baxter PA, Zhao X, Liu Z, Wadhwa L, Zhang Y, Su JM, Tan X, Yang J, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Blaney SM, Chintagumpala M, Hurwitz RL, Li XN.

Neuro Oncol. 2011 Jan;13(1):14-27. doi: 10.1093/neuonc/noq148. Epub 2010 Nov 12.

3.

Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.

Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt AJ, Szalay AA.

Clin Cancer Res. 2012 May 1;18(9):2579-90. doi: 10.1158/1078-0432.CCR-11-2394. Epub 2012 Feb 29.

4.

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.

Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, Yang J, Watkins DN, Rudin CM, Hallenbeck PL.

J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33. Epub 2007 Oct 30.

5.

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA.

J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57.

PMID:
17077357
6.

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, Forsyth PA.

Cancer Res. 2005 Nov 1;65(21):9982-9990. doi: 10.1158/0008-5472.CAN-05-1201.

7.

Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.

Poirier JT, Reddy PS, Idamakanti N, Li SS, Stump KL, Burroughs KD, Hallenbeck PL, Rudin CM.

J Gen Virol. 2012 Dec;93(Pt 12):2606-13. doi: 10.1099/vir.0.046011-0. Epub 2012 Sep 12.

PMID:
22971818
8.

Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.

Wei J, Wahl J, Nakamura T, Stiller D, Mertens T, Debatin KM, Beltinger C.

Gene Ther. 2007 Nov;14(22):1573-86. Epub 2007 Sep 27.

PMID:
17898797
9.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

10.

A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.

Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, Lesniak MS.

Mol Pharm. 2011 Oct 3;8(5):1559-72. doi: 10.1021/mp200161f. Epub 2011 Jun 30.

11.

Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.

Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero Y Calle M, Deleu L, Sommer C, Thomas N, Rommelaere J, Schlehofer JR.

Neuro Oncol. 2010 Aug;12(8):804-14. doi: 10.1093/neuonc/noq023. Epub 2010 Mar 18.

12.

Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.

Lamfers ML, Idema S, Bosscher L, Heukelom S, Moeniralm S, van der Meulen-Muileman IH, Overmeer RM, van der Valk P, van Beusechem VW, Gerritsen WR, Vandertop WP, Dirven CM.

Clin Cancer Res. 2007 Dec 15;13(24):7451-8.

13.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Dec 15;74(24):7260-73. doi: 10.1158/0008-5472.CAN-14-0876. Epub 2014 Oct 21.

14.

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.

Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342. Epub 2009 Apr 7.

15.

Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.

PLoS One. 2013 Jun 6;8(6):e65801. doi: 10.1371/journal.pone.0065801. Print 2013. Erratum in: PLoS One. 2014;9(6):e101827.

16.

Reovirus as an oncolytic agent against experimental human malignant gliomas.

Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA.

J Natl Cancer Inst. 2001 Jun 20;93(12):903-12.

PMID:
11416111
17.

Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus.

Wadhwa L, Hurwitz MY, Chévez-Barrios P, Hurwitz RL.

Cancer Res. 2007 Nov 15;67(22):10653-6.

18.

Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.

Vera B, Martínez-Vélez N, Xipell E, Acanda de la Rocha A, Patiño-García A, Saez-Castresana J, Gonzalez-Huarriz M, Cascallo M, Alemany R, Alonso MM.

PLoS One. 2016 Jan 25;11(1):e0147211. doi: 10.1371/journal.pone.0147211. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0157619.

19.

The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.

Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca EA, Kaur B, Date I.

Cancer Gene Ther. 2013 Aug;20(8):437-44. doi: 10.1038/cgt.2013.38. Epub 2013 Jul 5.

20.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

Supplemental Content

Support Center